<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Therasense Inc — News on 6ix</title>
    <link>https://6ix.com/company/therasense-inc</link>
    <description>Latest news and press releases for Therasense Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 27 Sep 2018 13:57:42 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/therasense-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-initiates-phase-2-clinical-trial-of-novel-vaccine-as-front-line-treatment-for-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-initiates-phase-2-clinical-trial-of-novel-vaccine-as-front-line-treatment-for-prostate-cancer</guid>
      <pubDate>Thu, 27 Sep 2018 13:57:42 GMT</pubDate>
      <description>OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer.</description>
    </item>
    <item>
      <title>OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomunes-phase-2-clinical-trial-of-proscavax-for-early-stage-prostate-cancer-is-now-included-on-clinicaltrialsgov</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomunes-phase-2-clinical-trial-of-proscavax-for-early-stage-prostate-cancer-is-now-included-on-clinicaltrialsgov</guid>
      <pubDate>Mon, 09 Jul 2018 15:32:41 GMT</pubDate>
      <description>OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov.</description>
    </item>
    <item>
      <title>OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-signs-work-order-for-phase-2-clinical-trial-of-proscavax-for-early-stage-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-signs-work-order-for-phase-2-clinical-trial-of-proscavax-for-early-stage-prostate-cancer</guid>
      <pubDate>Mon, 02 Jul 2018 18:39:41 GMT</pubDate>
      <description>OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer.</description>
    </item>
    <item>
      <title>OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-to-commence-phase-2-trial-of-proscavax-for-early-stage-prostate-cancer-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-to-commence-phase-2-trial-of-proscavax-for-early-stage-prostate-cancer-patients</guid>
      <pubDate>Wed, 20 Jun 2018 12:01:13 GMT</pubDate>
      <description>OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients.</description>
    </item>
    <item>
      <title>OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May</title>
      <link>https://6ix.com/company/therasense-inc/news/otc-markets-group-announces-lists-of-compliance-downgrades-and-caveat-emptor-designations-for-the-month-of-may-1</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/otc-markets-group-announces-lists-of-compliance-downgrades-and-caveat-emptor-designations-for-the-month-of-may-1</guid>
      <pubDate>Wed, 06 Jun 2018 20:02:39 GMT</pubDate>
      <description>OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May.</description>
    </item>
    <item>
      <title>OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-returns-protocol-to-scientific-review-committee-overseeing-phase-2-prostate-cancer-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-returns-protocol-to-scientific-review-committee-overseeing-phase-2-prostate-cancer-clinical-trial</guid>
      <pubDate>Wed, 28 Mar 2018 13:10:41 GMT</pubDate>
      <description>OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial.</description>
    </item>
    <item>
      <title>Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial</title>
      <link>https://6ix.com/company/therasense-inc/news/scientific-review-committee-meets-on-oncbiomunes-phase-2-prostate-cancer-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/scientific-review-committee-meets-on-oncbiomunes-phase-2-prostate-cancer-clinical-trial</guid>
      <pubDate>Thu, 22 Mar 2018 13:01:12 GMT</pubDate>
      <description>Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial.</description>
    </item>
    <item>
      <title>OncBioMune Announces Presentation at the 2018 AACR Annual Meeting</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-announces-presentation-at-the-2018-aacr-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-announces-presentation-at-the-2018-aacr-annual-meeting</guid>
      <pubDate>Tue, 20 Mar 2018 13:07:45 GMT</pubDate>
      <description>OncBioMune Announces Presentation at the 2018 AACR Annual Meeting.</description>
    </item>
    <item>
      <title>OncBioMune Appoints Robert Neal Holcomb to Board of Directors</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-appoints-robert-neal-holcomb-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-appoints-robert-neal-holcomb-to-board-of-directors</guid>
      <pubDate>Mon, 19 Mar 2018 13:24:45 GMT</pubDate>
      <description>OncBioMune Appoints Robert Neal Holcomb to Board of Directors.</description>
    </item>
    <item>
      <title>OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-selects-theradex-as-cro-for-two-phase-2-trials-of-proscavax-for-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-selects-theradex-as-cro-for-two-phase-2-trials-of-proscavax-for-prostate-cancer</guid>
      <pubDate>Thu, 08 Mar 2018 14:16:12 GMT</pubDate>
      <description>OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer.</description>
    </item>
    <item>
      <title>OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-submits-phase-2-protocol-to-urology-centers-of-north-texas</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-submits-phase-2-protocol-to-urology-centers-of-north-texas</guid>
      <pubDate>Wed, 28 Feb 2018 13:29:43 GMT</pubDate>
      <description>OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas.</description>
    </item>
    <item>
      <title>OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-provides-updates-on-two-phase-2-clinical-trials-of-proscavax-for-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-provides-updates-on-two-phase-2-clinical-trials-of-proscavax-for-prostate-cancer</guid>
      <pubDate>Mon, 26 Feb 2018 17:48:11 GMT</pubDate>
      <description>OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer.</description>
    </item>
    <item>
      <title>OncBioMune Provides Update on Market Activity</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-provides-update-on-market-activity</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-provides-update-on-market-activity</guid>
      <pubDate>Fri, 16 Feb 2018 21:23:42 GMT</pubDate>
      <description>OncBioMune Provides Update on Market Activity.</description>
    </item>
    <item>
      <title>OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-signs-letter-of-intent-to-initiate-phase-2-trial-of-proscavax-for-advanced-prostate-cancer-with-urology-clinics-of-north-texas</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-signs-letter-of-intent-to-initiate-phase-2-trial-of-proscavax-for-advanced-prostate-cancer-with-urology-clinics-of-north-texas</guid>
      <pubDate>Mon, 05 Feb 2018 13:45:10 GMT</pubDate>
      <description>OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas.</description>
    </item>
    <item>
      <title>70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time</title>
      <link>https://6ix.com/company/therasense-inc/news/70percent-of-advanced-prostate-cancer-patients-treated-with-proscavax-demonstrate-improvement-in-psa-doubling-time</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/70percent-of-advanced-prostate-cancer-patients-treated-with-proscavax-demonstrate-improvement-in-psa-doubling-time</guid>
      <pubDate>Wed, 10 Jan 2018 14:20:41 GMT</pubDate>
      <description>70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time.</description>
    </item>
    <item>
      <title>One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial</title>
      <link>https://6ix.com/company/therasense-inc/news/one-year-follow-up-shows-714percent-progression-free-survival-in-14-prostate-cancer-patients-treated-with-proscavax-in-phase-1-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/one-year-follow-up-shows-714percent-progression-free-survival-in-14-prostate-cancer-patients-treated-with-proscavax-in-phase-1-clinical-trial</guid>
      <pubDate>Thu, 21 Dec 2017 16:27:12 GMT</pubDate>
      <description>One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial.</description>
    </item>
    <item>
      <title>100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression</title>
      <link>https://6ix.com/company/therasense-inc/news/100percent-of-prostate-cancer-patients-completing-31-week-post-therapy-exam-after-treatment-with-oncbiomune-immunotherapy-show-no-disease-progression</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/100percent-of-prostate-cancer-patients-completing-31-week-post-therapy-exam-after-treatment-with-oncbiomune-immunotherapy-show-no-disease-progression</guid>
      <pubDate>Tue, 05 Dec 2017 13:30:12 GMT</pubDate>
      <description>100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression.</description>
    </item>
    <item>
      <title>80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up</title>
      <link>https://6ix.com/company/therasense-inc/news/80percent-of-prostate-cancer-patients-in-oncbiomune-phase-1-clinical-trial-of-proscavax-show-no-disease-progression-at-the-first-post-therapy-follow-up</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/80percent-of-prostate-cancer-patients-in-oncbiomune-phase-1-clinical-trial-of-proscavax-show-no-disease-progression-at-the-first-post-therapy-follow-up</guid>
      <pubDate>Mon, 13 Nov 2017 13:26:11 GMT</pubDate>
      <description>80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up.</description>
    </item>
    <item>
      <title>OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-preparing-to-initiate-trials-of-novel-therapeutic-ovarian-cancer-vaccine</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-preparing-to-initiate-trials-of-novel-therapeutic-ovarian-cancer-vaccine</guid>
      <pubDate>Tue, 17 Oct 2017 13:09:11 GMT</pubDate>
      <description>OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine.</description>
    </item>
    <item>
      <title>OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia</title>
      <link>https://6ix.com/company/therasense-inc/news/oncbiomune-cmo-producing-first-batch-of-tretinoin-for-acute-promyelocytic-leukemia</link>
      <guid isPermaLink="true">https://6ix.com/company/therasense-inc/news/oncbiomune-cmo-producing-first-batch-of-tretinoin-for-acute-promyelocytic-leukemia</guid>
      <pubDate>Fri, 29 Sep 2017 13:44:42 GMT</pubDate>
      <description>OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia.</description>
    </item>
  </channel>
</rss>